- A study explored total marrow irradiation (TMI) as a potential alternative to total body irradiation (TBI) for patients with multiple myeloma (MM) experiencing their first relapse after a significant period of remission, using a prospective phase 1 trial with varying doses of TMI.
- Thirteen patients were treated with different TMI doses (8 Gy, 10 Gy, 12 Gy, and 14 Gy), with only one experiencing dose-limiting toxicity at 12 Gy, and overall low acute toxicity rates were observed.
- After a median follow-up of 55 months, 70% of participants were alive, with notable responses to treatment, indicating TMI could effectively and safely improve outcomes in